SAN DIEGO, Sept. 2 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®. Diabetes patients enrolled in these cross-over design studies will receive an insulin analog alone and the Analog-PH20 treatment for 12 weeks each. Previous studies have demonstrated that the coinjection of rHuPH20 with an insulin analog results in a more physiologic fast-in, fast-out profile that enhances the mealtime glycemic control for each analog.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)
"These studies are designed to test whether the ultrafast profile of the Analog-PH20 insulin product will result in measurable benefits for patients with diabetes," stated Jonathan Lim, M.D., Halozyme's president and CEO. "We expect these studies will demonstrate that our rapid acting ultrafast insulin enables more patients to safely reach their A1C goal and to achieve better control of their blood glucose levels. Our partnership dialog is ongoing, and these studies will help support the clinical development and regulatory plans for a future partner."
These Phase 2 clinical trials, one in type 1 diabetes patients and the other in type 2 patients, will compare two ultrafast insulin analog products formulated with rHuPH20 to an active comparator, Humalog (insulin lispro). Each study will enroll approximately 110 patients and begins with a 4 to 6 week titration period where patients optimize their basal insulin dosing. Patients will then be randomized to receive either the Lispro-PH20 or Aspart-PH20 investigational study drugs and the active comparator three times daily for 12 weeks each in a random sequence. The primary endpoint of each study will be a comparison of glycemic control, as assessed by the change in A1C from baseline. Data regarding postprandial glucose levels, the proportion of patients that safely achieve A1C targets, rates of hypoglycemia, weight change and additional endpoints will be collected.
The goal of Halozyme's Ultrafast Insulin program is to develop a best-in-class mealtime insulin product compared to the currently prescribed analogs that participate in the growing $3.8 billion worldwide prandial insulin market. Additional information about these trials can be found at clinicaltrials.gov using the identifiers NCT01194245 and NCT01194258.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the design and anticipated results of clinical trials and the completion of those trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Halozyme Contact |
|
Robert H. Uhl |
|
Senior Director, Investor Relations |
|
(858) 704-8264 |
|
SOURCE Halozyme Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article